Minaris Expands GMP Cell Banking Capabilities in Philadelphia

Editor’s Take: By centralizing banking and testing in Philadelphia, Minaris Advanced Testing aims to reduce complexity for developers by synchronizing manufacturing, quality, and project management.

Minaris, a global cell and gene therapy (CGT) CDMO and biosafety testing organization, enhanced its dedicated GMP cell banking suites at its Philadelphia facility, a centralized hub for cell banking and biosafety testing. The upgraded suites provide a complete offering from GMP cell banking to integrated characterization testing, supporting clinical and commercial programs.

The specialized clean rooms feature multiple dedicated suites designed for concurrent cell banking programs, with infrastructure and workflows aligned with EU GMP Annex 1 and global regulatory standards. The suites incorporate controlled personnel and material flow, optimized cleanroom processes and classified environments including ISO 5 (Grade A) critical zones within ISO 7 (Grade B) background cleanrooms. It also brings modernized environmental monitoring and enhanced quality oversight to strengthen contamination control, supported by established tech transfer processes that help programs transition from development through commercial supply.

The enhancement reinforces Minaris Advanced Testing’s integrated model by uniting GMP cell banking with regulatory-aligned characterization and biosafety testing in a single U.S.-based hub. These capabilities, including sterility, mycoplasma, viral safety, and identity testing, simplify the management of Master and Working Cell Banks while providing clients with timely data and coordinated project management.

“Operational rigor is at the core of our GMP environments,” said Dr. Orla Cloak, Chief Executive Officer, Minaris. “These enhanced suites improve efficiency and predictability while maintaining the rigorous standards required for GMP production. With integrated characterization and daily visibility into program progress, we’re helping clients reach key milestones on the path to regulatory-ready cell banks.”